Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Enablement
Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear
While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading
AAM v. Neapco – Part III – The Dissent Faces a “Perfect Storm” of Conflated Doctrines
Since most of my last post discussing Judge Moore’s dissent focused on her criticism of the majority’s conclusion that the claimed invention—placing a tuned liner into a hollow “propshaft” to attenuate two modes of vibration—was directed to Hooke’s law and … Continue reading
The Unacknowledged Role of Section 112 in the Myriad Decisions
Guest post from Paul Cole, Lucas & Co., UK; introduction by Warren Woessner. In this interesting note, Paul Cole explores the possible effect on the Fed. Cir. and Supreme Court’s decisions about the patent-eligibility of “genomic DNA” of the arguable … Continue reading
Posted in Patent Eligible Subject Matter
Tagged application to bacterial genes, biotechnology, biotechnology law, blanket prohibition, BRCA1, cDNA, chemist or geneticist, Enablement, evaluation, full-length gene partial sequence, intellectual property, ip, Myriad, Patent Law, patent-eligibility, patents, Paul Cole, structural difference threshold, utility threshold, Warren Woessner, written description
Leave a comment
Edwards Lifesciences v. Corevalve – Pig Valve Implants Enabling
In Edwards Lifesciences AB v. Corevalve, Inc. (now a part of Medtronic), Appeal No. 2011-1215-1257 (Fed. Cir. Nov. 13, 2012), Corevalve challenged the validity of US Pat. No. 5,411,552 directed to a “transcather heart valve” on the basis that the … Continue reading
Posted in Enablement
Tagged Corevalve, Edwards Lifesciences AB, Enablement, FDA, Federal Circuit, Inc., Medtronic, Patent Law, Warren Woessner
1 Comment